Featured Story BioCentury & Getty ImagesMapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of ...

Featured Story BioCentury & Getty ImagesHard, measurable outcomes drive Express Scripts digital formulary

“I think that is reflective of how Express Scripts is moving forward.” The demonstration of hard clinical benefits and ROI for Express Scripts were the key elements that landed 10 digital platforms a ...

Featured Story BioCentury & Getty ImagesCharting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the ...

Featured Story BioCentury & Getty ImagesFrancis Collins’ 2020 vision for NIH

In his tenth year as NIH Director, Francis Collins is expanding the reach of marquee programs launched under his tenure, and growing the institutes’ footprint in artificial intelligence. In a ...

Featured Story Getty ImagesFinal reg reduces numbers of biopharma companies subject to CFIUS reviews

Final regulations implementing the Foreign Investment Risk Review Modernization Act of 2018 released on Jan. 14 represent a partial victory for the biopharma industry, but the process is still certain ...

Featured Story BioCentury & Getty ImagesThe AMR crisis is solvable -- but we must act together and fast

Antimicrobial resistance is one of the most serious threats to humanity. This year, a staggering 700,000 people will die from infections that cannot be treated by most or all available antibiotics. ...

Targets & Mechanisms BioCentury & Getty ImagesFor $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with ...

Targets & Mechanisms CPSF3 emerges as new synthetic lethality target in AML and sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas. The premise ...

Emerging Company Profile BioCentury & Getty ImagesBorisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

Alexis Borisy has launched EQRx to disrupt the biopharma world by developing and launching innovative therapies at “radically lower” prices than commercial competitors. With its first drug expected to ...

Emerging Company Profile BioCentury & Getty ImagesKyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The ...

Politics, Policy & Law BioCentury & Getty ImagesTrade deal elicits Chinese promises to align pharma IP with U.S. Hatch-Waxman paradigm

A combination of pressure from the U.S. government and admonitions from domestic and multinational innovative drug manufacturers have led the Chinese government to agree to align its pharmaceutical ...

Politics, Policy & Law Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and ...

Commentary BioCentury & Getty ImagesAll chips on immuno-oncology is not a good gamble

While first-generation immuno-oncology therapies are only the tip of the iceberg of what immune reprogramming promises to do for patients, the massive investment in the space has entered bubble ...

Finance BioCentury & Getty ImagesFrazier taking new company creation angle with $617M fund

For its latest and largest venture fund, Frazier Healthcare Ventures aims to conduct more company creation around novel targets while continuing to focus on its core areas of investment. The firm will ...

Finance BioCentury & Getty ImagesNovo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II ...

BioCentury ISSN 1097-7201